Navigation Links
Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy
Date:2/12/2009

Claims extend and strengthen Odyssey Thera's coverage to include GPCR directed screening and drug profiling.

SAN RAMON, Calif., Feb. 12 /PRNewswire/ -- Odyssey Thera, Inc. announced today that it has been granted a United States patent entitled "Fragment Complementation Assays for G-Protein-Coupled Receptors and their Signaling Pathways." The patent broadly covers methods for screening compounds and for identifying drug leads based on their ability to activate, inhibit or otherwise modulate G-protein-coupled receptors and the diverse signaling pathways linked to these receptors.

"This patent further extends and strengthens our deep patent estate in drug discovery and development technologies," said John K. Westwick, Ph.D., Odyssey Thera CEO and co-author on the patent. "GPCRs are among the most valued targets for drug discovery, and our proprietary technologies enable GPCR-directed drug discovery in a native biological context. The fluorescence-based assays described in this patent are the only available strategy for capturing GPCR activities, including responses of hetero-dimeric GPCR complexes and diverse downstream effector proteins, in living human cells. These powerful new tools are essential in our search for more effective therapies for cancer and other un-met medical needs."

This is the thirteenth patent issued to Odyssey Thera, and solidifies its leadership position in cellular assay and drug discovery technologies. The inventions covered by this patent (U.S. Patent No. 7,488,583) were made by Odyssey Thera scientists.

About Odyssey Thera, Inc.

Odyssey Thera, Inc. is a drug discovery company building therapeutic pipelines for oncology and other chronic diseases. Odyssey Thera's pathway-based approach centers on its proprietary protein-fragment complementation assay (PCA) technology, as well as the considerable body of trade secrets it has developed in screening technologies and the understanding of complex cellular biochemical networks.

To learn more about Odyssey Thera, please visit www.odysseythera.com.


'/>"/>
SOURCE Odyssey Thera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Odyssey Thera Granted U.S. Patent for Animal Imaging
2. Stereotaxis Highlights a Transatlantic Arrhythmia Procedure Collaboration With the Odyssey(TM) Network
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. LI-COR Introduces the Odyssey(R) Two-Color NIR Fluorescent Protein Molecular Weight Marker
5. Technical Note: E-PAGE(TM) 48- and 96-Well Gels on the Odyssey(R) Infrared Imaging System
6. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
9. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... YORK , January 20, 2017 ... Organization, cancer is one of leading causes of death ... 2012. Although the number of cancer related deaths increased ... 1990. Rising in incidence rate of various cancers continues ... to a research report by Global Market Insights, Inc. ...
(Date:1/19/2017)... Jan. 19, 2017  Market Research Future has a half cooked ... Liquid Biopsy is growing rapidly and expected to reach USD 450 ... Highlights ... Liquid Biopsy Market has been assessed as a swiftly growing market ... boom in the coming future. There has been a tremendous growth ...
(Date:1/19/2017)... Research and Markets ... the addition of the "Implantable Biomaterials Market Analysis ... report to their offering. Report Highlights: ... on current and future market trends to identify the investment opportunities ... base numbers Key market trends across the business segments, ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 /PRNewswire/ ... a privately-held immunotherapeutics company targeting infectious diseases, announced ... the merger of PharmAthene and Altimmune in an ... Fund, HealthCap, Truffle Capital and Redmont Capital. The ... immunotherapeutics company with four clinical stage and one ...
Breaking Biology Technology:
(Date:1/6/2017)... NEWARK, Calif. , Jan. 5, 2017  Delta ... introduced its iris scanning technology for automotive at CESĀ® ... GNTX ) to demonstrate the use of ... to identify and authenticate the driver in a car, ... automobiles during the driving experience. Delta ID ...
(Date:12/22/2016)... NEW YORK , December 22, 2016 ... global provider of secure solutions for the e-Government, Public Safety, HealthCare, ... a subsidiary of SuperCom, has been selected to implement and deploy ... county in Northern California , further expanding its ... ...
(Date:12/16/2016)... 16, 2016 Research and Markets has announced ... Global Forecast to 2021" report to their offering. ... The biometric vehicle access ... a CAGR of 14.06% from 2016 to 2021. The market is ... to reach 854.8 Million by 2021. The growth of the biometric ...
Breaking Biology News(10 mins):